艾滋病患者使用富马酸替诺福韦二吡呋酯、拉米夫定、依非韦伦联合治疗的疗效观察

Efficacy of combination therapy with tenofovir fumarate and dipivoxil,lamivudine and efavirenz in patients with acquired immune deficiency syndrome

目的分析艾滋病患者使用富马酸替诺福韦二吡呋酯、拉米夫定、依非韦伦的临床疗效。方法选择80例艾滋病患者,所有患者均接受富马酸替诺福韦二吡呋酯、拉米夫定、依非韦伦联合治疗,对比治疗前后患者血CD4细胞水平,观察临床疗效。结果患者治疗12个月后血CD4细胞水平为(458.12±12.80)个/μl明显高于治疗前的(205.27±8.90)个/μl,差异具有统计学意义(P<0.05)。80例患者治疗12个月后,显效40例,占比50.00%;有效31例,占比38.75%;无效9例,占比11.25%;总有效率为88.75%(71/80)。结论艾滋病患者使用富马酸替诺福韦二吡呋酯、拉米夫定、依非韦伦联合治疗疗效显著,能提高血CD4细胞水平,改善免疫能力,阻止病情进展,这一治疗方案不仅疗效理想,同时还具有较好的用药安全性。

Objective To analyze the clinical efficacy of combination therapy with tenofovir fumarate and dipivoxil,lamivudine and efavirenz in patients with acquired immune deficiency syndrome.Methods There were 80 patients with acquired immune deficiency syndrome,and they all received combination therapy with tenofovir fumarate and dipivoxil,lamivudine and efavirenz.The levels of blood CD4 cells before and after treatment were compared,and the clinical efficacy was observed.Results The blood CD4 cell level of the patients after 12 months of treatment was(458.12±12.80)cells/μl,which was significantly higher than(205.27±8.90)cells/μl before treatment,and the difference was statistically significant(P<0.05).After 12 months of treatment,40 cases were markedly effective,accounting for 50.00%;31 cases were effective,accounting for 38.75%;9 cases were invalid,accounting for 11.25%;the total effective rate was 88.75%(71/80).Conclusion Combination therapy with tenofovir fumarate and dipivoxil,lamivudine and efavirenz has significant efficacy on patients with acquired immune deficiency syndrome,which can improve the level of CD4 cells,improve the immune ability and prevent the progress of the disease.This treatment scheme not only has ideal efficacy,but also has good drug safety.